Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (391-400 of 466) with videos related to

Pageof 47
Sort By:
International Journal of Cancer|February 10, 2016
Telomere dysfunction and chromothripsisAurélie Ernst, David T W Jones, Kendra K Maass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.
Blood|March 23, 2017
Venetoclax and obinutuzumab in chronic lymphocytic leukemiaKirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, et al.
Bone Marrow Transplantation|January 16, 2026
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and SwitzerlandLinda Simon, Vladan Vucinic, Kai Rejeski, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Haematologica|July 18, 2020
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphomaLorenz Thurner, Sylvia Hartmann, Moritz Bewarder, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Pageof 47

Showing results (391-400 of 466) with videos related to

Sort By:
Pageof 47
International Journal of Cancer|February 10, 2016
Telomere dysfunction and chromothripsisAurélie Ernst, David T W Jones, Kendra K Maass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Nature Communications|July 29, 2017
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaGero Knittel, Tim Rehkämper, Darya Korovkina, et al.
Blood|March 23, 2017
Venetoclax and obinutuzumab in chronic lymphocytic leukemiaKirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, et al.
Bone Marrow Transplantation|January 16, 2026
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and SwitzerlandLinda Simon, Vladan Vucinic, Kai Rejeski, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Haematologica|July 18, 2020
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphomaLorenz Thurner, Sylvia Hartmann, Moritz Bewarder, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Pageof 47